

# Tadej AvÄin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1633703/publications.pdf>

Version: 2024-02-01

93  
papers

4,443  
citations

136885

32  
h-index

114418

63  
g-index

98  
all docs

98  
docs citations

98  
times ranked

5049  
citing authors

#	ARTICLE	IF	CITATIONS
1	Underdetection of Interstitial Lung Disease in Juvenile Systemic Sclerosis. Arthritis Care and Research, 2022, 74, 364-370.	1.5	13
2	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison. Clinical and Experimental Rheumatology, 2022, 40, 103-112.	0.4	3
3	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET. Clinical and Experimental Rheumatology, 2022, 40, 3-11.	0.4	12
4	Addressing mental health issues in immunocompromised adolescents with chronic diseases during the COVID-19 pandemic. Jornal De Pediatria, 2022, , .	0.9	1
5	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0
6	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0
7	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. Arthritis Care and Research, 2021, 73, 1490-1501.	1.5	60
8	Consensus-based recommendations for the management of juvenile systemic sclerosis. Rheumatology, 2021, 60, 1651-1658.	0.9	20
9	2019 EULAR points to consider for the assessment of competences in rheumatology specialty training. Annals of the Rheumatic Diseases, 2021, 80, 65-70.	0.5	12
10	The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. Nature Reviews Rheumatology, 2021, 17, 177-184.	3.5	35
11	Prophylactic Anticoagulation Therapy: Comment on the Article by Henderson et al. Arthritis and Rheumatology, 2021, 73, 1341-1342.	2.9	2
12	The expansion of human T-bet <sup>high</sup> CD21 <sup>low</sup> B cells is T cell dependent. Science Immunology, 2021, 6, eabh0891.	5.6	82
13	Case Report: Necrotizing Stomatitis as a Manifestation of COVID-19-Associated Vasculopathy. Frontiers in Pediatrics, 2021, 9, 800576.	0.9	2
14	Altered Homeostasis of Regulatory T Lymphocytes and Differential Regulation of STAT1/STAT5 in CD4+ T Lymphocytes in Childhood-onset Systemic Lupus Erythematosus. Journal of Rheumatology, 2020, 47, 557-566.	1.0	2
15	PIK3AP1 and SPON2 Genes Are Differentially Methylated in Patients With Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis (PFAPA) Syndrome. Frontiers in Immunology, 2020, 11, 1322.	2.2	7
16	The Clinical and Genetic Spectrum of 82 Patients With RAG Deficiency Including a c.256_257delAA Founder Variant in Slavic Countries. Frontiers in Immunology, 2020, 11, 900.	2.2	16
17	Pediatric APS: State of the Art. Current Rheumatology Reports, 2020, 22, 9.	2.1	19
18	Vaccination coverage in children with rheumatic diseases. Clinical and Experimental Rheumatology, 2020, 38, 164-170.	0.4	8

#	ARTICLE	IF	CITATIONS
19	Chronic non-bacterial osteomyelitis: a retrospective international study on clinical manifestations and response to treatment. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1255-1262.	0.4	3
20	Are diffuse and limited juvenile systemic sclerosis different in clinical presentation? Clinical characteristics of a juvenile systemic sclerosis cohort. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 49-61.	1.0	20
21	Flow Cytometric Determination of Actin Polymerization in Peripheral Blood Leukocytes Effectively Discriminate Patients With Homozygous Mutation in ARPC1B From Asymptomatic Carriers and Normal Controls. <i>Frontiers in Immunology</i> , 2019, 10, 1632.	2.2	14
22	Undifferentiated connective tissue disease: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000786.	1.8	28
23	The European network for care of children with paediatric rheumatic diseases: care across borders. <i>Rheumatology</i> , 2019, 58, 1188-1195.	0.9	15
24	American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019, 71, 579-590.	1.5	15
25	Vaccine immune response, autoimmunity and morbidity after neonatal blood exchange transfusion. <i>Vaccine</i> , 2019, 37, 4076-4080.	1.7	0
26	European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis – the SHARE initiative. <i>Rheumatology</i> , 2019, 58, 1607-1616.	0.9	165
27	Consensus-based recommendations for the management of juvenile localised scleroderma. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1019-1024.	0.5	76
28	Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000784.	1.8	19
29	Mixed connective tissue disease: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000783.	1.8	30
30	AB0944 – SJĀĀGRENĀĀMS SYNDROME IN CHILDREN: A CASE SERIES. , 2019, , .		0
31	STAT signaling as a marker of SLE disease severity and implications for clinical therapy. <i>Autoimmunity Reviews</i> , 2019, 18, 144-154.	2.5	14
32	European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides – the SHARE initiative. <i>Rheumatology</i> , 2019, 58, 656-671.	0.9	77
33	European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease – the SHARE initiative. <i>Rheumatology</i> , 2019, 58, 672-682.	0.9	103
34	Systemic lupus erythematosus: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000793.	1.8	66
35	Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. <i>Journal of Rheumatology</i> , 2019, 46, 190-197.	1.0	318
36	American College of Rheumatology Provisional Criteria for Global Flares in Childhood-onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018, 70, 813-822.	1.5	19

#	ARTICLE	IF	CITATIONS
37	The Slovene version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). <i>Rheumatology International</i> , 2018, 38, 363-369.	1.5	0
38	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2018-213030.	0.5	183
39	Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 319-327.	0.5	9
40	Ehlers-Danlos syndromes: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000790.	1.8	23
41	Educational initiatives and training for paediatric rheumatology in Europe. <i>Pediatric Rheumatology</i> , 2018, 16, 77.	0.9	10
42	CS-10â€¦Criteria for clinically relevant improvement in children & adolescents with childhood-onset systemic lupus erythematosus. , 2018, , .		0
43	Antiphospholipid syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000785.	1.8	38
44	The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1633-1643.	2.0	39
45	Functional Complement Analysis Can Predict Genetic Testing Results and Long-Term Outcome in Patients With Complement Deficiencies. <i>Frontiers in Immunology</i> , 2018, 9, 500.	2.2	6
46	The Role of STAT Signaling Pathways in the Pathogenesis of Systemic Lupus Erythematosus. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 164-181.	2.9	74
47	Increased Levels of STAT1 Protein in Blood CD4 T Cells from Systemic Lupus Erythematosus Patients Are Associated with Perturbed Homeostasis of Activated CD45RA <sup>+</sup> FOXP3 <sup>hi</sup> Regulatory Subset and Follow-Up Disease Severity. <i>Journal of Interferon and Cytokine Research</i> , 2017, 37, 254-268.	0.5	23
48	STAT5 phosphorylation in CD4 T cells from patients with SLE is related to changes in their subsets and follow-up disease severity. <i>Journal of Leukocyte Biology</i> , 2017, 101, 1405-1418.	1.5	18
49	European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1637-1641.	0.5	75
50	European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1788-1796.	0.5	139
51	Relationship Between Polymorphisms in Methotrexate Pathway Genes and Outcome of Methotrexate Treatment in a Cohort of 119 Patients with Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2017, 44, 1216-1223.	1.0	18
52	Paediatric Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017, 12, 145-165.	0.1	1
53	European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1965-1973.	0.5	105
54	Clinical and MRI outcome of cervical spine lesions in children with juvenile idiopathic arthritis treated with anti-TNF± drugs early in disease course. <i>Pediatric Rheumatology</i> , 2017, 15, 38.	0.9	14

#	ARTICLE	IF	CITATIONS
55	Acute rheumatic fever outbreak in southern central European country. <i>European Journal of Pediatrics</i> , 2017, 176, 23-29.	1.3	10
56	A prospective study on the natural history of patients with profound combined immunodeficiency: An interim analysis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1302-1310.e4.	1.5	71
57	Antiphospholipid Antibody Syndrome in Childhood. , 2017, , 377-392.		0
58	15th International Congress on Antiphospholipid Antibodies Task Force on Pediatric Antiphospholipid Syndrome Report. , 2017, , 291-306.		1
59	Management of Juvenile Idiopathic Arthritis: A Clinical Guide. <i>Paediatric Drugs</i> , 2016, 18, 397-412.	1.3	34
60	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2016, 68, 566-576.	2.9	427
61	Autoimmune and Inflammatory Manifestations in 247 Patients with Primary Immunodeficiency—a Report from the Slovenian National Registry. <i>Journal of Clinical Immunology</i> , 2016, 36, 764-773.	2.0	22
62	Distribution of MEFV gene mutations and R202Q polymorphism in the Serbian population and their influence on oxidative stress and clinical manifestations of inflammation. <i>Pediatric Rheumatology</i> , 2016, 14, 39.	0.9	10
63	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>RMD Open</i> , 2016, 2, e000161.	1.8	57
64	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 481-489.	0.5	338
65	Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 816-824.	1.0	46
66	Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. <i>Lancet</i> , The, 2016, 387, 671-678.	6.3	168
67	Autoimmune hepatitis as a presenting manifestation of mixed connective tissue disease in a child Case report and review of the literature. <i>Pediatric Rheumatology</i> , 2015, 13, 47.	0.9	10
68	Age-Related Differences in Percentages of Regulatory and Effector T Lymphocytes and Their Subsets in Healthy Individuals and Characteristic STAT1/STAT5 Signalling Response in Helper T Lymphocytes. <i>Journal of Immunology Research</i> , 2015, 2015, 1-13.	0.9	29
69	Prescribing adrenaline autoinjectors in Slovenian children. <i>Clinical and Translational Allergy</i> , 2015, 5, P109.	1.4	2
70	Clinical Features and Genetic Background of the Periodic Fever Syndrome with Aphthous Stomatitis, Pharyngitis, and Adenitis: A Single Center Longitudinal Study of 81 Patients. <i>Mediators of Inflammation</i> , 2015, 2015, 1-8.	1.4	55
71	Pediatric Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2015, 17, 27.	2.1	33
72	The carrier rate and spectrum of MEFV gene mutations in central and southeastern European populations. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S19-23.	0.4	2

#	ARTICLE	IF	CITATIONS
73	Health related quality of life measure in systemic pediatric rheumatic diseases and its translation to different languages: an international collaboration. <i>Pediatric Rheumatology</i> , 2014, 12, 49.	0.9	6
74	Clinical features of childhood granulomatosis with polyangiitis (wegenerâ€™s granulomatosis). <i>Pediatric Rheumatology</i> , 2014, 12, 18.	0.9	85
75	European registry of babies born to mothers with antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 217-222.	0.5	84
76	How to useâ€™ lupus anticoagulants: Tableâ€™1. <i>Archives of Disease in Childhood: Education and Practice Edition</i> , 2013, 98, 52-57.	0.3	4
77	Taxonomy for systemic lupus erythematosus with onset before adulthood. <i>Arthritis Care and Research</i> , 2012, 64, 1787-1793.	1.5	141
78	Antiphospholipid Antibody Syndrome. , 2012, , 1641-1648.		0
79	Anti-â€™glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their 'innocent' profile?. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 380-383.	0.5	85
80	Exploring the Binding Sites of Anti-Infliximab Antibodies in Pediatric Patients With Rheumatic Diseases Treated With Infliximab. <i>Pediatric Research</i> , 2011, 69, 243-248.	1.1	33
81	Influenza and Autoimmunity. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 619-626.	1.8	38
82	Microthrombotic/Microangiopathic Manifestations of the Antiphospholipid Syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , 2009, 36, 109-125.	2.9	30
83	Syngotropic hypersensitivity reaction associated with infliximab and leflunomide combination therapy in a child with psoriatic arthritis. <i>Journal of Cutaneous Pathology</i> , 2009, 36, 991-994.	0.7	6
84	Chapter 10 Pediatric Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2009, , 125-138.	0.1	0
85	A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2008, 59, 206-213.	6.7	100
86	Pediatric Antiphospholipid Syndrome: Clinical and Immunologic Features of 121 Patients in an International Registry. <i>Pediatrics</i> , 2008, 122, e1100-e1107.	1.0	193
87	Antiphospholipid syndrome in children. <i>Current Opinion in Rheumatology</i> , 2008, 20, 595-600.	2.0	30
88	Early-onset osteoarthritis due to otospondylomegaepiphyseal dysplasia in a family with a novel splicing mutation of the COL11A2 gene. <i>Journal of Rheumatology</i> , 2008, 35, 920-6.	1.0	13
89	Chapter 13 Pediatric Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2007, 6, 169-285.	0.1	0
90	Antiphospholipid antibodies in response to infection. <i>Current Rheumatology Reports</i> , 2007, 9, 212-218.	2.1	78

#	ARTICLE	IF	CITATIONS
91	Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. Journal of Pediatrics, 2006, 148, 683-686.	0.9	100
92	Nasal septal perforation: a novel clinical manifestation of systemic juvenile idiopathic arthritis/adult onset Still's disease. Journal of Rheumatology, 2005, 32, 2429-31.	1.0	24
93	Evans Syndrome Associated With Antiphospholipid Antibodies. Journal of Pediatric Hematology/Oncology, 2003, 25, 755-756.	0.3	16